ArticleFrontiers in oncology2012
The promise of the anti-idiotype concept.
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects.Reviews in medical virology · 2025Review
- GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system.NPJ precision oncology · 2025Review
- New insights into antibody structure with implications for specificity, variable region restriction and isotype choice.Nature reviews. Immunology · 2025Review
- Article
- The past, present, and future of anti-idiotype antibodies.Frontiers in immunology · 2025Article
- A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2.Journal of virology · 2024Article
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Article
- Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design.NPJ vaccines · 2021Article
- Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases.Future science OA · 2020Review
- Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy.Antibodies (Basel, Switzerland) · 2020Review
- CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading.International journal of molecular sciences · 2019Article
- Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease.Journal of immunology research · 2019Review
- The Promise of Anti-idiotype Revisited.Frontiers in immunology · 2019Review
- Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.Frontiers in immunology · 2019Article
- Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.Antibody therapeutics · 2019Article
- Immune Response Regulation by Antigen Receptors' Clone-Specific Nonself Parts.Frontiers in immunology · 2018Review
- A generalized quantitative antibody homeostasis model: antigen saturation, natural antibodies and a quantitative antibody network.Clinical & translational immunology · 2017Article
- A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune Memory.Frontiers in immunology · 2017Article
- Can the Immune System Perform a t-Test?PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A basic tenet of antibody-based immunity is their specificity to antigenic determinates from foreign pathogen products to abnormal cellular components such as in cancer. However, an antibody has the potential to bind to more than one determinate, be it an antigen or another antibody. These observations led to the idiotype network theory (INT) to explain immune regulation, which has wax and waned in enthusiasm over the years. A truer measure of the impact of the INT is in terms of the ideas that now form the mainstay of immunological research and whose roots are spawned from the promise of the anti-idiotype concept. Among the applications of the INT is understanding the structural implications of the antibody-mediated network that has the potential for innovation in terms of rational design of reagents with biological, chemical, and pharmaceutical applications that underlies concepts of reverse immunology which is highlighted herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.